Equillium (EQ) Net Cash Flow (2018 - 2026)
Equillium (EQ) posted quarterly Net Cash Flow of $31.0 million for Q1 2026, up 966.61% year-over-year from $2.9 million in Q1 2025, and up 1177.1% quarter-over-quarter from -$2.9 million in Q4 2025.
Equillium (EQ) Net Cash Flow (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Net Cash Flow for 9 consecutive years, with $31.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 966.61% year-over-year to $31.0 million; the TTM figure through Mar 2026 stood at $46.8 million (up 1507.18% YoY), while the FY2025 annual figure was $12.1 million, up 340.59% from the prior year.
- Net Cash Flow improved to $31.0 million in Q1 2026 per EQ's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $33.3 million in Q4 2022 and bottomed at -$34.6 million in Q1 2023.
- Historically, Net Cash Flow has averaged $639411.8 across 5 years, with a median of -$621000.0 in 2024.
- Annual changes were most pronounced in 2025 — Net Cash Flow sank 387.76% — and 2026, when it jumped 966.61%.
- Equillium's Net Cash Flow stood at $33.3 million in 2022, then slumped by 133.44% to -$11.2 million in 2023, then jumped by 124.84% to $2.8 million in 2024, then slumped by 204.04% to -$2.9 million in 2025, then surged by 1177.1% to $31.0 million in 2026.
- Business Quant data shows EQ's Net Cash Flow at $31.0 million in Q1 2026, -$2.9 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.14 Mn |
| Jun 30, 2026 | -4.14 Mn |
| Mar 31, 2026 | 31.04 Mn |
| Mar 31, 2026 | 31.04 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Sep 30, 2025 | 21.64 Mn |
| Sep 30, 2025 | 21.64 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 4.34 Mn |
| Sep 30, 2024 | 4.34 Mn |
| Jun 30, 2024 | -621,000.00 |
| Jun 30, 2024 | -621,000.00 |
| Mar 31, 2024 | -11.63 Mn |
| Mar 31, 2024 | -11.63 Mn |